StockNow
Log in
Tariffs/TradeIMPORTANT

USTR says they have commenced a Section 301 probe of Germany regarding pharmaceuticals, to determine whether persistent underpayment for innovative pharmaceutical products by Germany is unreasonable or discriminatory

News detail

USTR will hold a hearing in connection with these investigations on September 22nd, 2026.Potential means/tools that could follow: supplemental discounts in exchange for confidentiality of negotiated prices; and mandatory variable rate rebates. USTR Greer:"I am particularly concerned with news that Germany is fast-tracking legislation that would further reduce its spending on innovative pharmaceuticals"

What do investors think?

Curious what other investors think?Log in to see reactions and join the conversation.
Log in to view reactions

StockNow uses AI to translate and analyze information and does not guarantee its accuracy or completeness.

Today's market highlights

A selection of stories drawing attention in the market.

See more
Geopolitics

Gulf official tells CNN “50:50” chance US and Iran could reach deal by Friday, CNN reports; Iranian delegation does not include IRGC, which would need to sign off on details of provisional agreement

Geopolitics

The draft agreed to by Iranian and Omani negotiators awaits final approval from Iran’s supreme leader, two regional officials told The Associated Press on Wednesday

Geopolitics

Only 'one or two issues' remain unresolved in Iran-Oman talks, a senior diplomatic source tells Al Jazeera